Investor Relations

Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.

News Releases

Date Title and Summary
Toggle Summary electroCore and UpScript Launch Program to Offer Direct-to-Patient Telemedicine Option for gammaCore™ in the United States
BASKING RIDGE, N.J., July 17, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, announced today a program with UpScript, a digital healthcare platform, offering a direct-to-patient telemedicine option for gammaCore™ non-invasive vagus nerve
Toggle Summary electroCore, Inc. Announces Additions to Board of Directors in Connection with Recently Completed Initial Public Offering
BASKING RIDGE, N.J., July 10, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Carrie S. Cox as Chairman of its Board of Directors, and Michael G. Atieh and Stephen L. Ondra, M.D.
Toggle Summary electroCore to Present Additional Research for Non-invasive Vagus Nerve Stimulation (nVNS) in Headache Disorders at the 60th Annual Meeting of the American Headache Society
BASKING RIDGE, N.J. , June 28, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, announced today it will present six abstracts across three primary headache disorders at the 60 th Annual Meeting of the American Headache Society (AHS) ( June
Toggle Summary electroCore, Inc. Announces Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering
BASKING RIDGE, N.J. , June 28, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR) today announced that the underwriters of its previously announced initial public offering of common stock have exercised in full their option to purchase an additional 780,000 shares of common
Toggle Summary electroCore, Inc. Announces Closing of Initial Public Offering
BASKING RIDGE, N.J., June 26, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq: ECOR ) today announced the closing of its initial public offering of 5,200,000 shares of common stock at a public offering price of $15.00 per share. The proceeds from this offering, net of
Toggle Summary electroCore, Inc. Announces Pricing of Initial Public Offering
BASKING RIDGE, N.J. , June 21, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) today announced the pricing of its initial public offering of 5,200,000 shares of common stock at a public offering price of $15.00 per share. All of the shares of common stock are being offered by
Toggle Summary gammaCore® Receives FDA Clearance for the Acute Treatment of Pain Associated with Migraine Headache in Adult Patients
gammaCore® Receives FDA Clearance for the Acute Treatment of Pain Associated with Migraine Headache in Adult Patients Basking Ridge, NJ, January 29, 2018  – electroCore, LLC (electroCore), a commercial-stage bioelectronic medicine company, announced today that it has received 510(k) clearance from
Toggle Summary electroCore Completes $70 Million Series B Funding Round
Investment to fund commercialization of gammaCore ®  and further clinical development of nVNS   Basking Ridge, NJ, November 29, 2017  – electroCore, a U.S.-based bioelectronic medicine healthcare company advancing better patient therapies through superior approaches to neuromodulation, announced
Toggle Summary electroCore Announces Results from gammaCore® (non-invasive vagus nerve stimulator) Study in Migraine at the 18th Congress of the International Headache Society
PRESTO demonstrates clinical benefit of gammaCore in the acute treatment of migraine compared to sham  Basking Ridge, NJ, September 11, 2017 –  electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, announced the first results
Toggle Summary Publicis Health CEO Joins electroCore’s Board of Directors
Nick Colucci Brings Invaluable Healthcare Communications Expertise to Enhance electroCore’s Continued Growth   Basking Ridge, NJ, August 29, 2017 –  electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, today announced that